CERUS CORP

CERUS CORP is a biomedical products company that develops and commercializes the INTERCEPT Blood System to enhance blood safety. This system uses proprietary technology to control biological replication, aiming to reduce blood-borne pathogens in donated blood components for transfusion. The INTERCEPT Blood System is designed for use with platelets, plasma, red blood cells, and to produce INTERCEPT Fibrinogen Complex (IFC) and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for platelets (platelet system) and the INTERCEPT Blood System for plasma (plasma system) have received various regulatory approvals and certifications. These include FDA approval in the U.S. and CE Certificates of Conformity under Medical Devices Regulation 2017/745, allowing the CE Mark for sale in the European Union and other recognizing jurisdictions. These systems are marketed and sold globally, including in the U.S., parts of Europe, the Commonwealth of Independent States (CIS), the Middle East, Latin America, and selected countries in other regions. CERUS CORP also has FDA approval for the INTERCEPT Blood System for Cryoprecipitation. This system utilizes the plasma system to produce IFC for treating and controlling bleeding, including massive hemorrhage, associated with fibrinogen deficiency. It also produces pathogen reduced plasma, cryoprecipitate reduced. The company sells its platelet and plasma systems through a direct sales force and distributors. IFC or disposable kits for manufacturing IFC are sold in the U.S. via a direct sales force.